Ghost Tree Capital’s Immunovant IMVT Stock Holding History

Ghost Tree Capital’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$6.13M	Sell	215,000 -45,000	-17%	-$1.33M	1.85%	23
2024 Q2	$6.86M	Buy	260,000 +135,000	+108%	+$3.84M	2.15%	18
2024 Q1	$4.04M	Buy	+125,000	New	+$4.56M	1.12%	31
2023 Q4	–	Sell	-130,000	Closed	-$4.99M	–	60
2023 Q3	$4.99M	Buy	+130,000	New	+$2.94M	1.64%	20
2021 Q2	–	Sell	-250,000	Closed	-$3.49M	–	60
2021 Q1	$4.01M	Sell	250,000 -50,000	-17%	-$1.32M	0.94%	37
2020 Q4	$13.9M	Sell	300,000 -225,000	-43%	-$10.4M	3.09%	12
2020 Q3	$18.5M	Hold	525,000	–	–	5.34%	6
2020 Q2	$12.8M	Sell	525,000 -185,000	-26%	-$3.96M	3.37%	11
2020 Q1	$11.1M	Sell	710,000 -90,000	-11%	-$1.35M	2.93%	11
2019 Q4	$12.7M	Buy	+800,000	New	+$8.96M	2.42%	12

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Ghost Tree Capital's IMVT Position: Q3 2024 in Review

Ghost Tree Capital reduced its Immunovant (IMVT) stake by 17% in Q3 2024, selling an estimated $1.33M and leaving 215,000 shares worth $6.13M. The position accounts for 1.85% of the portfolio, ranked #23.

Ghost Tree Capital first reported a position in IMVT in Q4 2019 and has held it in 10 quarters since. The position peaked at $18.5M in Q3 2020. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2024.

Ghost Tree Capital held 215,000 shares of Immunovant worth $6.13M as of Q3 2024.
Ghost Tree Capital sold 45,000 Immunovant shares in Q3 2024, an estimated $1.33M.
Immunovant made up 1.85% of Ghost Tree Capital's portfolio in Q3 2024, its #23 holding.
Ghost Tree Capital first reported a position in Immunovant in Q4 2019 and has held it in 10 quarters since.
Ghost Tree Capital's Immunovant position peaked at $18.5M in Q3 2020.
181 funds tracked by Wall St. Rank held Immunovant as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.